2. Signaling Pathways
  3. GPCR/G Protein
  4. GCGR

GCGR

Glucagon Receptor

GCGR

Related Products

PDF 0.98 MB

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P1141A
    GLP-1(9-36)amide TFA
    		Antagonist 98.61%
    GLP-1(9-36)amide TFA is a major metabolite of glucagon-like peptide-1-(7-36) amide formed by the enzyme dipeptidyl peptidase-4 (DPP-4). GLP-1(9-36)amide TFA acts as an antagonist to the human pancreatic GLP-1 receptor.
    GLP-1(9-36)amide TFA
  • HY-P10018
    Bamadutide
    		Agonist 99.94%
    Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes.
    Bamadutide
  • HY-P10032
    NN1177
    		Agonist 99.54%
    NN1177 is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
    NN1177
  • HY-P3375A
    Mazdutide TFA
    		Agonist 99.67%
    Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (Ki: 17.7 nM and 15.9 nM, respectively) and GLP-1R (Ki: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC50: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D).
    Mazdutide TFA
  • HY-112679
    GLP-1 receptor agonist 2
    		Agonist 98.70%
    GLP-1 receptor agonist 2 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.
    GLP-1 receptor agonist 2
  • HY-P3102
    GLP-1(32-36)amide
    		98.44%
    GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.
    GLP-1(32-36)amide
  • HY-141840
    GLP-1R modulator C5
    		Modulator 99.81%
    GLP-1R modulator C5 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 1.59 ± 0.53 μM).
    GLP-1R modulator C5
  • HY-50675
    GRA Ex-25
    		Inhibitor 99.07%
    GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.
    GRA Ex-25
  • HY-50159
    Glucagon receptor antagonist-3
    		Antagonist 99.78%
    Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonist-3
  • HY-P990013
    Gulgafafusp alfa
    		Inhibitor
    Gulgafafusp alfa is a human IgG2κ antibody targeting the glucagon-like peptide 1 receptor GLP1R.
    Gulgafafusp alfa
  • HY-148212
    GLP-1R agonist 17
    		Agonist 99.82%
    GLP-1R agonist 17 (Compound example 232) is a GLP-1 receptor agonist. GLP-1R agonist 17 shows excellent agonism on a GLP-1 receptor. GLP-1R agonist 17 can be used for the research of cardiovascular metabolic diseases.
    GLP-1R agonist 17
  • HY-P10019
    Pegsebrenatide
    		Agonist
    Pegsebrenatide (NLY01) is a blood-brain barrier-penetrant GLP-1R agonist. Pegsebrenatide alleviates retinal inflammation and neuronal death secondary to ocular hypertension. Pegsebrenatide significantly delays onset and reduces disease severity in experimental autoimmune encephalomyelitis. Pegsebrenatide inhibits the formation of A1 reactive astrocytes in nerve cells and reduces the loss of retinal ganglion cells and dopaminergic neurons. Pegsebrenatide exerts neuroprotective effects in a mouse model of Parkinson's disease by directly preventing microglia-mediated conversion of astrocytes to the A1 neurotoxic phenotype. Pegsebrenatide can be used for research on glaucoma, Parkinson's disease, and multiple sclerosis.
    Pegsebrenatide
  • HY-P5815
    GLP-1 (1-36) amide (human, rat)
    		98.10%
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells.
    GLP-1 (1-36) amide (human, rat)
  • HY-141842
    GLP-1R modulator L7-028
    		Modulator 99.47%
    GLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC50 11.01 ± 2.73 μM).
    GLP-1R modulator L7-028
  • HY-P10031
    SAR441255
    		Agonist 99.77%
    SAR441255 is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 stimulates receptor activity and drives cAMP accumulation. SAR441255 can be used for the research of type 2 diabetes, obesity.
    SAR441255
  • HY-P10031A
    SAR441255 TFA
    		99.93%
    SAR441255 TFA is a GLP-1R/GCGR/GIPR agonist, with human EC50 values of 1.03 pM, 1.01 pM, and 0.73 pM, respectively. SAR441255 TFA stimulates receptor activity and drives cAMP accumulation. SAR441255 TFA can be used for the research of type 2 diabetes, obesity.
    SAR441255 TFA
  • HY-P3617
    Glucagon (22-29)
    		Agonist 98.12%
    Glucagon (22-29) is partial agonist of Glucagon (19–29). Glucagon specifically inhibits the Ca2+ pump in liver plasma membranes independently of adenylate cyclase activation.
    Glucagon (22-29)
  • HY-148844
    GCGR antagonist 2
    		Antagonist 98.17%
    GCGR antagonist 2, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an Kd value of 2.3 nM, and inhibits rat receptor with an IC50 value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis.
    GCGR antagonist 2
  • HY-116854
    NNC 92-1687
    		Antagonist 98.74%
    NNC 92-1687 is a non-peptide competitive human glucagon receptor antagonist (IC50=20 μM; Ki=9.1 μM). NNC 92-1687 can be used in the research of type 2 diabetes.
    NNC 92-1687
  • HY-50158
    Glucagon receptor antagonist-2
    		Antagonist 99.23%
    Glucagon receptor antagonist-2 is a highly potent glucagon receptor antagonist.
    Glucagon receptor antagonist-2
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity